FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

Season 9 Episode 2  ·  Jun 12, 2023, 06:00 PM
Headliner
Share
Subscribe

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

Share
Subscribe
Next
FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air